Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (May 2018)
8 slides from Pyc Therapeutics's investor presentation, May 11, 2018
Slide 1: Phylogica Investor Presentation May 2018
For personal use only Phylogica Investor Presentation May 2018 1
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: The problem – the 'undruggable target'
The problem – the ‘undruggable target’ For personal use only Drug target Drug 1 2 3 The highest The cell membrane is Drugs are unable value drug specifically designed to reach the 80% of targets exist to keep ‘foreign’ targets that reside inside cells substances out inside cells The insight: in 1988
Slide 4: Phylogica's solution – leverage nature
Phylogica‘s solution – leverage nature For personal use only Peptide Build a unique drug library with 500 billion peptides library • Our core patent underpins our drug library based on the genomes of viruses, bacteria and other organisms • We cut the genome of each organism into fragments to create
Slide 5: Validation of platform across multiple contexts, including in animal studies
Validation of platform across multiple contexts, including in animal studies For personal use only Concept Disease model Outcome Disease + Disease treatment Normal tissue Muscle-cell Duchenne Muscular successfully Dystrophy treated by FPP-cargo Cell penetrating Breast cancer peptide inhibited by + D
Slide 6: What's new in 2018?
What’s new in 2018? For personal use only Drug Screening Analytics In vivo libraries tools capability outcomes 2017 36% of phyla represented Manual – low Insufficient data to Very encouraging – – not specifically throughput use advanced clear point of designed for FPPs analytics differentiation Comi
Slide 7: Near term milestones
Near term milestones For personal use only 3Q2018 4Q2018 Delivery Platform Systemic delivery of Cre in vivo Cancer vaccine T-cell expansion in vivo CRISPR Delivery of Cas9 ex vivo Target Product Profile Evaluation of PK extension in vivo 7
Slide 8: Investment highlights
Investment highlights For personal use only Platform addresses a large unmet need – 80% of drug targets exist inside the cell Phylogica‘s proprietary platform provides Pharma customers the solution to getting a working cargo inside cells The platform has been validated in animals – the transition fr